Similar Papers

Paper Title
Journal
Date
Author
Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Naveen Pemmaraju ... Marina Konopleva
Blood | VOL. 130
Naveen Pemmaraju, et. al.Naveen Pemmaraju ... Marina Konopleva
25 Jun 2021
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era
Naveen Pemmaraju ... Marina Y Konopleva
Blood | VOL. 134
Naveen Pemmaraju, et. al.Naveen Pemmaraju ... Marina Y Konopleva
13 Nov 2019
Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy
Naveen Pemmaraju ... Hagop Kantarjian
Blood | VOL. 138
Naveen Pemmaraju, et. al.Naveen Pemmaraju ... Hagop Kantarjian
05 Nov 2021
Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Naveen Pemmaraju ...
Blood | VOL. 138
Naveen Pemmaraju, et. al.Naveen Pemmaraju ...
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Brentuximab vedotin and nivolumab for cHL.
-
Blood | VOL. 145
--
16 Jan 2025
B-1 B cells lose self-control in SCD.
David R Gibb ... Sean R Stowell
Blood | VOL. 145
David R Gibb, et. al.David R Gibb ... Sean R Stowell
16 Jan 2025
Is it time to screen for multiple myeloma?
Irene M Ghobrial ... Floris Chabrun
Blood | VOL. 145
Irene M Ghobrial, et. al.Irene M Ghobrial ... Floris Chabrun
16 Jan 2025
Daratumumab for maintenance in myeloma.
Cyrille Touzeau ... Aurore Perrot
Blood | VOL. 145
Cyrille Touzeau, et. al.Cyrille Touzeau ... Aurore Perrot
16 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.